Kornimate/medical-research-clean huggingface dataset:
burn out among medical family doctors

Conditions: Burnout, Professional; Mental Health Wellness 1; Anxiety; Depressive Disorder; Occupational Stress

Summary: the main objective of this study is to assess the burnout prevalence among french general practitioners in private practice. as secondary outcomes, this study aim to measure the impact of sociodemographic variables, organizational practice models and workload. the investigators also intend to characterize the prevalence of depression, anxiety, fatigue and stress, drugs and alcohol consumption, use of psychotropic medication, and preferred strategies to cope with their symptoms.

the boum protocol is designed to provide a better understanding of the current burnout prevalence among french general practitioners, as well as its risk and protective factors. in order to fulfil those objectives, the methodologist estimated a 1536 individuals sample size, using an expected prevalence of severe burnout ranged between 10% and 20% (from the the egprn study - soler, j.k., et al., burnout in european family doctors: the egprn study. family practice, 2008. 25(4): p. 245-265), thus allowing the investigators to retrieve results with a 95% confidence level and a 2% error margin. all analyses will be performed in a bilateral formulation for a 5% alpha error under the stata® software (version 13, statacorp, college station, us). a difference will be considered statistically significant for p\<0.05. the population will be described as frequency and percentage for the categorical variables, and as mean ± standard deviation or median \[interquartile range\] for the quantitative variables, according to their statistical distribution (normality studied by the shapiro-wilk test). confidence intervals for population prevalence will be characterised with a binomial test. comparisons between groups of burnout will be performed using chi2 or fisher's exact test for the categorical variables (followed by a marascuillo post-hoc tests if needed), and by an anova or kruskal-wallis test if normality and homoscedasticity not respected (bartlett test) for the quantitative variables (followed by tukey-kramer or dunn tests when necessary). finally, considering the variables clinically relevant and those with a pertinent univariate analysis results, a multivariate analyse of ordinal polynomial regression type will be proposed; its results will be expressed as relative risk with 95% confidence intervals and presented as a forest-plot.

Eligibility criteria:
inclusion criteria: * general practitioners working in france exclusion criteria: * none

Keywords: general practitioners private practice models, organizational behavior and behavior mechanisms test anxiety scale surveys and questionnaires cross-sectional studies
a pharmacokinetic study comparing vi-0521 with placebo in obese adolescents

Conditions: Pediatric Obesity; Childhood Obesity

Summary: the primary objective of this study is to describe the pharmacokinetic profiles of vi-0521 in obese adolescents.


Eligibility criteria:
inclusion criteria: * provide written informed consent; * provide written assent (of study subject); * adolescent ≥12 and \<18 years of age; * have a bmi ≥ the 95th percentile of bmi for age and gender; * female subjects must be using adequate contraception; * willing and able to comply with all study requirements exclusion criteria: * condition or disease interfering with metabolism; * any medical treatment with insulin; * hyperthyroidism, or clinically significant hypothyroidism; * any history of bipolar disorder or psychosis, major depressive disorder, or history of suicidal behavior or ideation, or any use of antidepressant medications; * use of chronic systemic glucocorticoid or steroid therapy; * history of any eating disorders; * any history of laxative abuse; * prior bariatric surgery; * any history of nephrolithiasis; * any history of epilepsy, or treatment with anti-seizure medications; * positive urine drug screen; * current smoker or smoking cessation within the previous 3 months of screening; * obesity of a known genetic or endocrine origin; * treatment with any over-the-counter or prescription weight loss drug, or attention-deficit/hyperactivity disorder (adhd); * allergy or hypersensitivity to phentermine or topiramate or history of anaphylaxis to any drug; * use of any investigational medication or device for any indication or participation in a clinical study within 30 days prior to screening; or * any medical or surgical condition which would impair the ability of the subject to complete the study, compromise the quality of study data, or pose an unacceptable risk to the safety of the subject.

Keywords: adolescent obesity childhood obesity qsymia pharmacokinetics vi-0521 phentermine topiramate
soft tissue therapy in managing procedural pain among neonates.

Conditions: Neonatal Disorder

Summary: effect of soft tissue therapy in managing procedural pain among neonates admitted in neonatal intensive care unit. this study focuses on the procedural pain management with the help of soft tissue manipulation which includes various techniques like stroking, petrissage manipulations.

background: neonatal intensive care unit (nicu) is a specialized unit created for sick and premature newborns. there are various painful procedures through which neonates have to undergo during the nicu stay. the most common procedure is the blood tests for the laboratory investigations which include the heel lancing and venipuncture. pain is the one of the cause of the development of the acute stress in neonates soft tissue therapy has considered as the major contributory factor of in reducing the procedural pain among neonates admitted nicu. there is no documentation on soft tissue therapy in managing procedural pain in neonates. purpose: to determine the effects of soft tissue therapy in managing procedural pain among neonates admitted in nicu. methods and materials: the study will recruit neonates who underwent for various painful procedures in nicu such as venous and arterial puncture, capillary puncture, pulmonary mechanical ventilation, tracheal intubation, removal of adhesive tapes, the introduction of various drains etc. preterm, term, full terms neonates stable neonates. the samples will be taken via stratified random sampling technique. neonates with unstable vitals are to be excluded from the study. discussion: to best of our knowledge, this will be the first study determining the effects of soft tissue therapy in procedural pain on neonates admitted in nicu. the role of neonatal physiotherapist in nicu is to provide diagnosis and treatment to admitted newborns. massage therapy is considered as an effective management technique in pain management. in this study soft tissue therapy will be applied to neonates especially in context with procedural pain. there are various painful procedures performed to check the prognosis of neonates. keywords: neonatal; newborns; infant; nicu; procedural pain; massage therapy.

Eligibility criteria:
inclusion criteria: 1. neonates who underwent various painful procedures in nicu such as venous, arterial and capillary puncture, mechanical ventilation for pulmonary causes, tracheal intubation, adhesive tapes removal, insertion of various drains etc. 2. preterm, term, post terms neonates 3. stable neonates. exclusion criteria: 1. post-surgical cases 2. parents of neonates who are not willing to enroll their infant in study. 3. neonates with congenital anomalies. 4. neonates with extreme low birth weight.

Keywords: neonatal newborns infant nicu procedural pain massage therapy
hcv rna fingerstick assay as useful point of care of diagnostic tool for drug users in brussels

Conditions: Hepatitis C, Chronic

Summary: the main objective of this study is to assess the interest (linkage to care) of the cepheid genexpert hcv vl fingerstick test in brussels among drug users or former users in contact with the réseau hépatite c bruxelles organization through different partners of this network.


Eligibility criteria:
inclusion criteria: * (ex) drug users * a risk of hepatitis c infection * french speaking * either patient with a positive serology for hcv who have never performed hcv rna by polymerase chain reaction (pcr) by a peripheral venous sampling (due to difficult venous access, financial problem, medical insurance problem or other reasons) either patient with a suspicion of reinfection for whom the hcv rna pcr by peripheral venous sampling is not reimbursed by health insurance exclusion criteria: * age \<18 years * cepheid genexpert hcv vl fingerstick will not use to assess the sustained virological response (svr) at 12 weeks after the end of an antiviral treatment

Keywords: drug user, point-of-care of molecular diagnostics, hepatitis c rna, fingerstick, genexpert hcv viral load, linkage to care
oxulumis® suprachoroidal microcatherization of triesence® in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the oxulumis® device for a randomized treatment with two dose levels of triesence® in subjects with diabetic macular edema.

twenty-four (24) week, randomized, two-arm, single-masked, clinical trial to evaluate safety, tolerability, and to explore the efficacy of two dose levels of suprachoroidal triamcinolone acetonide suspension (triesence®, 2.4 mg, and 4.0mg) administered using the oxulumis® microcatheterization device in subjects with previously treated diabetic macular edema. after a screening period, approximately 20 eligible diabetic macular edema subjects will be treated using a 1:1 ratio to receive a single administration of one of two dose levels of triamcinolone acetonide (low dose, 2.4mg. or mid-dose, 4.0mg, respectively). if for any reasons treatment in randomized subjects cannot be completed, additional consecutive subjects will be randomized until the target number of approximately 20 treated subjects is reached. from week 4, subjects will be assessed for the need for follow-on treatment. the follow-up period after treatment administration will be up to twenty-four (24) weeks.

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus. * diabetic macular edema involving the center of the fovea in the study eye * best-corrected visual acuity in the study eye of ≤73 (early treatment of diabetic retinopathy study) etdrs letters (approximate snellen equivalent of 20/40 or worse) * short-lived, limited, or no response to prior ocular injection therapy exclusion criteria: * macular edema is considered due to a cause other than diabetes mellitus in the study eye. * condition, in the study eye, in which visual acuity is not expected to improve from the resolution of macular edema * macular laser photocoagulation or panretinal laser photocoagulation in the study eye performed within sixteen (16) weeks prior to screening. * active proliferative diabetic retinopathy (pdr) or sequelae of pdr in the study eye. * active malignancy or history of malignancy within the past five years. * prior intravitreal (ivt) treatment with anti-vascular endothelial growth factor (vegf) in the study eye: last injection within four weeks, before screening * prior ocular treatment with steroids in the study eye: last injection (intra- or periocular) with triamcinolone acetonide within three (3) months, with dexamethasone implant (ozurdex®) within six (6) months before screening. * prior treatment with longer duration steroid implants (e.g., fluocinolone acetonide ivt implant, iluvien®) is exclusionary. * prior treatment with suprachoroidal steroids is exclusionary. * uncontrolled diabetes with a hemoglobin a1c (hba1c) \> 12% or any other uncontrolled systemic disease at screening.
incidence of macular edema after panretinal photocoagulation (prpc) performed in a single session versus four sessions in diabetic patients.

Conditions: Diabetes Type 1 or 2 With Diabetic Retinopathy

Summary: the aim of this study is to show that prpc performed in a single session using a pascal laser leads to better management of the disease (better rate of regression of neovessels, lower risk of a loss of visual acuity in the long term related to macular edema), a saving of time and better comfort for both patient and doctor.


Eligibility criteria:
inclusion criteria: * diabetes type 1 or 2 * subjects with severe non-proliferative or early proliferative diabetic retinopathy (according to the alfediam classification) * subjects with central macular thickness less than or equal to 350 µm according to spetralis oct * subjects registered with a social security agency * subjects who have provided written informed consent * subjects aged 18 or above exclusion criteria: * pregnancy * breastfeeding women * patients presenting a contra-indication to mydriaticum and neosynephrine * history of glaucoma or non-controlled ocular hypertension * blindness in one eye * history of renal insufficiency requiring dialysis, or kidney or pancreas transplantation * unbalanced diabetes requiring, in the previous 4 months, intensive insulin therapy. * central macular thickness greater than 350 µm * visual acuity less than 20/32 measured using an etdrs chart * proliferative diabetic retinopathy associated with "high risk factors" (extensive prepapillary neovessels and/or preretinal or prepapillary neovessels associated with preretinal of intravitreal hemorrhage) * macular edema due to causes other than diabetic retinopathy (venous occlusion, uveitis) or occurring in a context of vitreomacular traction * already started prpc * history of eye surgery or yag laser capsulotomy performed during the preceding 6 months * subjects under legal supervision or guardianship
the use of tadalafil in confirmed covid-19 pneumonia.

Conditions: COVID; Sars-CoV2; ARDS, Human

Summary: our goal is to assess the effects of tadalafil in the setting of confirmed covid-19 pneumonia. in particular we plan to assess its effects on oxygen saturation, p:f ratio, and mixed central venous oxygen we plan to recruit all hospitalized patients at santa barbara cottage hospital with a confirmed covid19 pneumonia (positive pcr + clinical signs/symptoms of lower respiratory disease) who meet the berlin definition of ards and have access to measure a mixed venous oxygen saturation. for the purposes of obtaining mixed central venous oxygen, all participating patients will already have an internal jugular central venous catheter in place for inclusion in this study. since all patients will be intubated, their legally authorized representative (lar) will be approached to discuss the study and asked to participate in the study by an icu physician, either the attending physician or a medical resident. informed consent will be obtained from the lar by an icu attending physician or resident involved in the study prior to participation. patients who meet the above eligibility criteria will have baseline levels of mixed central venous oxygen, oxygen saturation, p:f ratio, blood pressure and pao2 recorded. each patient will then receive tadalafil 40mg once. the above listed parameters will be monitored again 30 minutes after drug administration and 4 hours after drug administration. no other medication or ventilator changes will be made during this time period outside of emergent changes in the setting of patient deterioration. we will continue to analyze the data in the event of emergent ventilator changes.


Eligibility criteria:
inclusion criteria: * hospitalized patients at sbch with confirmed covid19 pneumonia (pcr + clinical signs/symptoms of lower respiratory disease) * patients currently on a ventilator * patients who meet the berlin definition of ards * patients who have access to measure a mixed venous oxygen saturation (i.e., patients with an internal jugular central venous catheter) * patient and/or legally authorized representative is willing/able to provide informed consent exclusion criteria: * as tadalafil is currently a fda class b1 medication, indicating that little information is available, pregnant women along with women who are actively breastfeeding will be excluded from this series. * all patients under 18 * patients who are routinely taking nitrate medications * all patients using tadalafil daily for pulmonary arterial hypertension (note: patients using tadalafil intermittently for erectile dysfunction may still participate in the study)
covid-19: sars-cov-2-cz-preval-ii study

Conditions: COVID-19; SARS-CoV-2 Infection

Summary: the aim of the sars-cov-2-cz-preval-ii study is to quantify the prevalence of participants with antibodies against sars-cov-2 and/or cell immunity against sars-cov-2 in specific subjects cohorts.

the aim of the sars-cov-2-cz-preval-ii study is to quantify the prevalence of participants with antibodies against sars-cov-2 and/or cell immunity against sars-cov-2 in four specific cohorts: participants with chronic illness, healthy volunteers participating in the study of the czech academy of science, healthcare workers, and healthy volunteers that participated in the "herd immunity study sars-cov-2-cz-preval" in may 2020. the primary aim of the study is to estimate the number of people with anti-sars-cov-2-antibodies, i.e., people with covid-19 history, or with vaccination against covid-19. antibodies test will focus on two main proteins of virus sars-cov-2: s-protein and n-protein. the secondary aims of the study are: * quantitative analysis of cellular immunity and the other relevant markers, * estimation of the proportion of participants with asymptomatic covid-19 infection * quantification of anti-sars-cov-2 antibodies and cell immunity according to individual risk factors.

Eligibility criteria:
inclusion criteria: * signed informed consent * willingness to complete the study questionnaire * demographic criteria - age 18 years old and more * clinical criteria - without acute health problems * time criteria - sample collection in the defined period time exclusion criteria: * none

Keywords: antibodies cell immunity
effect of laryngeal mask airway on image quality n pediatric patients undergoing magnetic resonant imaging

Conditions: Airway Obstruction

Summary: this study compare the effects of oral airway vs lma in preventing anesthesia-induced partial airway obstruction, in an attempt to lessen mri motion artifacts, which would result in improvements in image quality.

magnetic resonance image (mri) is a frequently used imaging technique especially in oncological patients, where it is used for diagnosis, following up response to treatment and later for detection of possible recurrence. the main problem encountered with mri is the long time required for completion of the imaging, during which the patient is required to lie still. patients who are unable to lie still require sedation or general anesthesia (ga). almost all pediatric patients are uncooperative, making ga, the standard of care for pediatric mri. several general anesthetic techniques including airway management by endotracheal tube \& various supraglottic devices (lma) have been described. choice of technique by anesthesiologist is influenced by the patient's age, craniofacial and airway anatomy, procedure duration, \& illness acuity.

Eligibility criteria:
inclusion criteria: * asa і and ii patients * age under 18 years . * the patient will need ga and patient scheduled for mri brain. exclusion criteria: * glasgow coma scale ≤ 8 * emergency patient with full stomach. * distorted upper airway anatomy making intubation with ga mandatory.
the impact of rapid diagnostic methods in the diagnosis of fungal infections in intensive care units of assiut university hospital

Conditions: Fungal Infection

Summary: the diagnosis of invasive fungal disease remains challenging in the clinical laboratory. the use of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (maldi-tof ms) for the identification of filamentous fungi as well as its application for antifungal resistance testing and strain typing will be evaluated.

fungal infections are life-threatening opportunistic infections that have emerged as a major cause of morbidity and mortality in critically ill patients. yeast infections,mainly candida spp., remain much more frequent than mold infections. among mold infections, aspergillus spp. represent the most frequently isolated filamentous fungi in these circumstances .candida species are the most common cause of nosocomial fungal infections and the fourth most common source of hospital-acquired infections. candidiasis is an infection caused by candida, mostly limited to the skin, nails and mucous membranes. however, it can cause serious systemic infections. candidiasis is an opportunistic infection occurring in presence of predisposing factors like extensive and prolonged administration of broad-spectrum antimicrobials, corticosteroids, immunosuppressive agents and cytotoxic drugs, diabetes mellitus, hiv, chronic renal failure, haemodialysis, renal transplantation or indwelling urinary catheter.the pathogenicity of candida spp. is related to a combination of microbial factors such as their ability to grow at 37°c, polymorphism, biofilm formation, hydrolytic enzyme secretion, and phenotypic switching. candida species are identified by different phenotypic methods including examination of their morphological features, analysis of their ability of carbohydrates assimilation and/or fermentation, and their ability of assimilating different nitrogen compounds. numerous antifungal classes are used to treat candida infections; polyenes, azoles, echinocandins and allylamines. these antifungals are used with varying efficacy depending on the type, site of infection and the susceptibility of different candida species. azoles are the most frequently used antifungal drugs to treat candida infections as they achieve high success rates even over short durations of therapy. however, resistance among previously susceptible candida species has emerged following the expanded use of antifungal agents. antifungal susceptibility testing methods including broth dilution, disk diffusion and e test are now available with species-specific breakpoints developed by the clinical and laboratory standards institute (clsi) for multiple antifungal agents.

Eligibility criteria:
inclusion criteria: * patients of all age group and both sex with clinically suspected fungal infection at intensive care units of assiut university hospital will be included. exclusion criteria: * -patients who are on antifungal treatment and refuse to take part will be excluded from the study.
effects of salvianolate injection on myocardial microcirculation in patients with acute stemi after primary pci

Conditions: STEMI - ST Elevation Myocardial Infarction

Summary: to evaluate the influence of salvianolate injection on myocardial microcirculation perfusion in subjects with stemi who underwent primary pci

this is a prospective, randomized, double-blind and controlled study.536 subjects of stemi who underwent primary pci within the first 12 hours will be enrolled.all patients were assigned to receive 300mg of asprin and ≥300mg of clopidogrel as loading dose,and following 100mg and 75mg once daily respectively.patients were assigned to receive salvianolate injection or 0.9% sodium chloride injection in catherter room setting,and following similar medicine once daily respectively for 7 days.myocardial circulation perfusion will be checked with mmediate coronary angiography parameters,ecg,echocardiographic，ck-mb.the major adverse cardiovascular events will be observed.

Eligibility criteria:
inclusion criteria: 1. informed consent must be obtained prior to any study procedure. 2. age\>18 years. 3. subjects of stemi who underwent primary pci within the first 12 hours. exclusion criteria: 1. allergic to salvianolate injection 2. mechanical complications 3. history of severe renal or hepatic insufficiency 4. pregnant or breastfeeding women 5. pool compliance,greater risks result from the study